Busulfan (IV) and Fludarabine followed by post-allogeneic transplantation Cyclophosphamide for Graft-versus-Host Disease Prophylaxis in patients with hematologic malignancies.

Trial Profile

Busulfan (IV) and Fludarabine followed by post-allogeneic transplantation Cyclophosphamide for Graft-versus-Host Disease Prophylaxis in patients with hematologic malignancies.

Completed
Phase of Trial: Phase II

Latest Information Update: 21 Sep 2016

At a glance

  • Drugs Busulfan (Primary) ; Cyclophosphamide (Primary) ; Fludarabine (Primary)
  • Indications Graft-versus-host disease; Haematological malignancies; Leukaemia; Lymphoma; Multiple myeloma
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 06 Jul 2015 Status changed from active, no longer recruiting to completed as per ClinicalTrials.gov record.
    • 14 Dec 2012 Planned end date changed from 1 Oct 2013 to 1 Oct 2014 as reported by ClinicalTrials.gov.
    • 14 Dec 2011 Status changed from recruiting to active, no longer recruiting as reported by M.D. Anderson Cancer Center.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top